CONEXEU SCIENCES INC.

Reported by

BOGART DAVID ROBERT

FORM 4

(Statement of Changes in Beneficial Ownership)

Filed 09/28/26 for the Period Ending 09/25/26

Address	50 WEST LIBERTY STREET, SUITE 880 RENO, NV, 89501
Telephone	604-315-4722
CIK	0002066836
Symbol	CNXU
SIC Code	3842 - Orthopedic, Prosthetic, and Surgical Appliances and Supplies
Industry	Biotechnology & Medical Research
Sector	Healthcare
Fiscal Year	10/31

FORM 4

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *	2. Issuer Name **and** Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
Bogart David Robert (Last) (First) (Middle)	**Conexeu Sciences Inc. [CNXU]** 3. Date of Earliest Transaction (MM/DD/YYYY) **9/25/2026**	__X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) **Chief Commercial Officer**
50 WEST LIBERTY STREET, SUITE 880 (Street)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person
RENO NEVADA 89501 (City) (State) (Zip/Postal Code) **UNITED STATES** (Country)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8) Code	V	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) Amount	(A) or (D)	Price	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	**9/25/2026**		**M** (1)		**750,000**	**A**	**$0.001**	**1,812,500**	**D**	
Common Stock								**431,250**	**I**	**By 0865546 B.C. Ltd.** (2)

Table II - Derivative Securities Beneficially Owned (*e.g.*, puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8) Code	V	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) (A)	(D)	6. Date Exercisable and Expiration Date: Date Exercisable	Expiration Date	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4): Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Performance Warrants	**$0.001**	**9/25/2026**		**M** (1)			**750,000**	(3)	**6/5/2030** (3)	**Common Stock**	**750,000**	**$0** (3)	**250,000**	**D**	

Explanation of Responses:

(1) The transaction is also exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act.

(2) Held by 0865546 B.C. Ltd., over which the Reporting Person has sole voting and dispositive power.

(3) The Performance Warrants were granted on June 5, 2025 and have an exercise price of $0.001 and a term of 5 years. The Performance Warrants were granted for services rendered to the issuer and no price was paid for the Performance Warrants. 750,000 Performance Warrants have vested. The remaining 250,000 Performance Warrants will vest and be exercisable upon the Issuer submitting a 510(k) application to the United States Food and Drug Administration.

Reporting Owners

Reporting Owner Name / Address	Relationships: Director	10% Owner	Officer	Other
Bogart David Robert				

50 WEST LIBERTY STREET, SUITE 880 RENO NEVADA 89501 UNITED STATES	**X**		**Chief Commercial Officer**	

Signatures

/s/ David Bogart	**9/28/2026**
**Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

***** If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

****** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

* Form 4: SEC 1474 (03-26).